Compare BridgeBio Pharma Inc (BBIO) vs Alphabet Inc Class A (GOOGL) Price & Performance

BridgeBio Pharma IncTrade

Alphabet Inc Class ATrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Alphabet Inc Class A — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Alphabet Inc Class A trades at $346.63 (market cap $4.36T). The key difference: Alphabet Inc Class A is far larger — about 262.5× BridgeBio Pharma Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

	BBIO	GOOGL
Market Cap	$16.61B	$4.36T
Sector	Health	Media
52-Week High	$90.17	$402.62
52-Week Low	$47.29	$199.32
Enterprise Value	$18.16B	$4.25T
Dividend Yield	—	0.25%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

No Aura AI signal available yet.

Alphabet Inc Class A

Alphabet (GOOGL) trades at $357.52, up 0.91% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $9.11 versus $2.87 forecast. Revenue grew to $402.84 billion in 2025 with net income margin expanding to 32.8%. Recent developments include YouTube subscription price increases and AI infrastructure partnerships.

Alphabet presents a compelling investment case with strong earnings momentum and dominant market position. The primary opportunity lies in AI-driven growth and cloud expansion, though risks include antitrust scrutiny and competitive pressures. With 85% analyst buy ratings and a $426.28 consensus target representing 19% upside, the stock offers attractive potential despite regulatory headwinds.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BBIO

BridgeBio beats Q2 estimates, confirms $1B+ 2026 sales goal and plans three product launches by 2027.Seeking Alpha · 20 hours agoBullish View details →

GOOGL

Google's Gemini AI hits 1 billion monthly users, becoming its fastest-growing product ever.Forbes · 17 hours agoBullish Google's Gemini app hits 1 billion monthly users, rivaling ChatGPT's growth pace.TechCrunch · 18 hours agoBullish Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 20 hours agoNeutral View details →

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.